| 0 m B.A. | 3 m Q | 6 m Visit | 9 m Q | 12 m Visit | 15 m Q | 18 m Visit | 21 m Q | 24 m F.A. |
---|---|---|---|---|---|---|---|---|---|
Primary outcome measures | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Joint space width | x | Â | Â | Â | Â | Â | Â | Â | x |
Pain score (WOMAC) | x | Â | Â | Â | Â | Â | Â | Â | x |
Function score (WOMAC) | x | Â | Â | Â | Â | Â | Â | Â | x |
Secondary outcome measures | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Subchondral bone quality | x | Â | Â | Â | Â | Â | Â | Â | x |
Stiffness score (WOMAC) | x | x | x | x | x | x | x | x | x |
Quality of life (EuroQol EQ-5D) | x | x | x | x | x | x | x | x | x |
Medical consumption | x | x | x | x | x | x | x | x | x |
Side effects | Â | x | x | x | x | x | x | x | x |
CTX-II | x | Â | x | Â | x | Â | x | Â | x |
Possible confounders/Effect modifiers | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Type of OA (localised – generalised) | x |  |  |  |  |  |  |  |  |
Radiological severity | x | Â | Â | Â | Â | Â | Â | Â | x |
Joint function | x | Â | Â | Â | Â | Â | Â | Â | x |
Age | x | Â | Â | Â | Â | Â | Â | Â | Â |
Gender | x | Â | Â | Â | Â | Â | Â | Â | Â |
Activity level | x | x | x | x | x | x | x | x | x |
Co-interventions | x | x | x | x | x | x | x | x | x |
Compliance (BMQ) | Â | x | x | x | x | x | x | x | x |
Compliance (pill count) | Â | Â | x | Â | x | Â | x | Â | x |